Updated:
bioAffinity Technologies
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage lung cancer and other diseases of the lung. The Company’s first...
Overview
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage lung cancer and other diseases of the lung. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is especially useful for patients whose lung cancer screening or other scan reveals a pulmonary nodule.
General information
Firm type
Asset Manager
Year founded
2014
Location
Region
North America
Country
United States
City
San Antonio
Corporate office
3300 Nacogdoches Road, Suite 216, San Antonio, TX 78217, United States
Additional offices
Science Research Laboratories, The University of Texas at San Antonio, San Antonio, TX
Principals
Maria Zannes
President & CEO
Sector focus
Frequently asked questions
What does bioAffinity Technologies actually do?
The company developed and sells CyPath Lung, a noninvasive diagnostic test that uses flow cytometry and AI on sputum samples to detect lung cancer at early stages. The test is processed at Precision Pathology Laboratory Services, a wholly owned, CLIA-certified subsidiary in San Antonio. In a 2023 Respiratory Research publication, CyPath Lung demonstrated 92% sensitivity in high-risk patients.
Who runs investment and operational decisions at bioAffinity Technologies?
Maria Zannes serves as President and CEO, leading the company since its 2014 founding. The firm has not publicly disclosed a separate chief investment officer or capital allocation committee. Public shareholders set broad corporate direction following the firm's 2022 IPO.
Does bioAffinity Technologies participate in fund commitments or make external investments?
There is no public evidence that bioAffinity Technologies operates an investment fund, makes fund commitments, or conducts direct venture deals. The company functions as an operating entity commercializing its own diagnostic technology, with capital deployed internally toward R&D, clinical trials, and sales.
What are CyPath Lung's known performance metrics?
A 2023 trial published in Respiratory Research reported 92% sensitivity and 87% specificity in high-risk patients with pulmonary nodules under 20 millimeters. The test also demonstrated 95% Area Under the Curve with a 99% Negative Predictive Value, making it effective for ruling out cancer and reducing unnecessary biopsies.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: